/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $12 billion, Bio-Techne operates through Protein Sciences, and Diagnostics and Genomics segments.
The biotech major is expected to announce second-quarter results on Thursday, Feb. 6. Ahead of the event analysts expect Bio-Techne to report a non-GAAP profit of $0.33 per share, the same as the $0.33 per share reported in the year-ago quarter. While the company has surpassed Wall Street’s bottom-line expectation thrice over the past four quarters, it has missed the estimates on one other occasion. Its adjusted EPS of the last reported quarter increased 5.7% year-over-year to $0.37 exceeding analysts' estimates by 8.8%.
